SBP Group (01177): The latest research data on "ACTRII A/B monoclonal antibodies" will be announced at ECO in 2026.
China Biologic Pharmaceutical (01177) announced that its subsidiary, the Sun Pharma Group Co., Ltd. ("Sun Pharma"), has independently developed the innovative drug TQF6422 "ActRII A/B Monoclonal Antibody," and the preclinical research data has been announced at the 2026 European Congress on Obesity (ECO).
SBP GROUP (01177) announced that the subsidiary company Zhengda Tianqing Pharmaceutical Group Co., Ltd. ("Zhengda Tianqing") independently developed the innovative drug TQF6422 "ActRII A/B monoclonal antibody", and the preclinical research data has been presented at the 2026 European Congress on Obesity (ECO).
TQF6422 is a fully human monoclonal antibody targeting ActRII A/B, which specifically binds to the ActRII A/B receptor and blocks its ligands (Activin, Myostatin) mediated signaling, promoting skeletal muscle growth and enhancing fat breakdown, thus achieving a dual effect of weight loss and muscle gain.
Related Articles
On May 13th, CHINAHONGQIAO(01378) spent 299 million Hong Kong dollars to repurchase 8.9 million shares.
NEW WORLD DEV (00017) clarifies three major market rumors: there is no significant progress in potential investments, an agreement has not been reached on contract changes for 11 SKIES, and the reset deadline for financing terms is uncertain.
BeOne Medicines Ltd. (06160): Baiyueda has been approved by the US FDA to become the first and currently the only BCL2 inhibitor for the treatment of relapsed/refractory mantle cell lymphoma in the United States.
On May 13th, CHINAHONGQIAO(01378) spent 299 million Hong Kong dollars to repurchase 8.9 million shares.
NEW WORLD DEV (00017) clarifies three major market rumors: there is no significant progress in potential investments, an agreement has not been reached on contract changes for 11 SKIES, and the reset deadline for financing terms is uncertain.
BeOne Medicines Ltd. (06160): Baiyueda has been approved by the US FDA to become the first and currently the only BCL2 inhibitor for the treatment of relapsed/refractory mantle cell lymphoma in the United States.
RECOMMEND
Two Mainland Accounting Firms Approved for H‑Share Audits, Lowering Listing Costs and Deepening Mainland–Hong Kong Market Integration**The Ministry of Finance, the CSRC, and Hong Kong’s Accounting and Financial Reporting Council have approved two additional mainland accounting firms—RSM China and ShineWing—to conduct H‑share audit work, marking the first expansion of the list since 2010.
11/05/2026
HKEX Tightens Rules on Auditor Dismissals as Sudden “Audit Firm Switches” Raise Governance Concerns
11/05/2026
The Chip Stock Frenzy Is Still Accelerating
11/05/2026
